GREEN after consultant/specialist initiation: 50mg tablets: use in post-menopausal women with breast cancer as per NICE NG101. (Decision date - December 2019)
Cost-effective to prescribe generically
GREY: 150mg tablets
DO NOT PRESCRIBE (DNP): Not to be prescribed by brand - Bondronat. (Decision date - August 2019)